The evolution of commercial drug delivery technologies

doi:10.1038/s41551-021-00698-w

Review

. 2021 Sep;5(9):951-967.

doi: 10.1038/s41551-021-00698-w. Epub 2021 Apr 1.

The evolution of commercial drug delivery technologies

Ava M Vargason¹, Aaron C Anselmo², Samir Mitragotri^{3

4}

Affiliations

¹ Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
² Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. aanselmo@email.unc.edu.
³ John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA. mitragotri@seas.harvard.edu.
⁴ Wyss Institute for Biologically Inspired Engineering, Cambridge, MA, USA. mitragotri@seas.harvard.edu.

PMID: 33795852
DOI: 10.1038/s41551-021-00698-w

Review

The evolution of commercial drug delivery technologies

Ava M Vargason et al. Nat Biomed Eng. 2021 Sep.

. 2021 Sep;5(9):951-967.

doi: 10.1038/s41551-021-00698-w. Epub 2021 Apr 1.

Authors

Ava M Vargason¹, Aaron C Anselmo², Samir Mitragotri^{3

4}

Affiliations

¹ Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
² Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. aanselmo@email.unc.edu.
³ John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA. mitragotri@seas.harvard.edu.
⁴ Wyss Institute for Biologically Inspired Engineering, Cambridge, MA, USA. mitragotri@seas.harvard.edu.

PMID: 33795852
DOI: 10.1038/s41551-021-00698-w

Abstract

Drug delivery technologies have enabled the development of many pharmaceutical products that improve patient health by enhancing the delivery of a therapeutic to its target site, minimizing off-target accumulation and facilitating patient compliance. As therapeutic modalities expanded beyond small molecules to include nucleic acids, peptides, proteins and antibodies, drug delivery technologies were adapted to address the challenges that emerged. In this Review Article, we discuss seminal approaches that led to the development of successful therapeutic products involving small molecules and macromolecules, identify three drug delivery paradigms that form the basis of contemporary drug delivery and discuss how they have aided the initial clinical successes of each class of therapeutic. We also outline how the paradigms will contribute to the delivery of live-cell therapies.

PubMed Disclaimer

Cited by

Structural flexibility of apolipoprotein E-derived arginine-rich peptides improves their cell penetration capability.
Takechi-Haraya Y, Ohgita T, Usui A, Nishitsuji K, Uchimura K, Abe Y, Kawano R, Konaklieva MI, Reimund M, Remaley AT, Sato Y, Izutsu KI, Saito H. Takechi-Haraya Y, et al. Sci Rep. 2023 Nov 8;13(1):19396. doi: 10.1038/s41598-023-46754-0. Sci Rep. 2023. PMID: 37938626 Free PMC article.
Emerging Trends and Translational Challenges in Drug and Vaccine Delivery.
Kumar P, Agrahari V. Kumar P, et al. Pharmaceutics. 2024 Jan 11;16(1):98. doi: 10.3390/pharmaceutics16010098. Pharmaceutics. 2024. PMID: 38258108 Free PMC article.
Assessment of In Vitro Release Testing Methods for Colloidal Drug Carriers: The Lack of Standardized Protocols.
Gómez-Lázaro L, Martín-Sabroso C, Aparicio-Blanco J, Torres-Suárez AI. Gómez-Lázaro L, et al. Pharmaceutics. 2024 Jan 12;16(1):103. doi: 10.3390/pharmaceutics16010103. Pharmaceutics. 2024. PMID: 38258113 Free PMC article. Review.
A Comprehensive Review of Stimuli-Responsive Smart Polymer Materials-Recent Advances and Future Perspectives.
Balcerak-Woźniak A, Dzwonkowska-Zarzycka M, Kabatc-Borcz J. Balcerak-Woźniak A, et al. Materials (Basel). 2024 Aug 28;17(17):4255. doi: 10.3390/ma17174255. Materials (Basel). 2024. PMID: 39274645 Free PMC article. Review.
Exogeneous metal ions as therapeutic agents in cardiovascular disease and their delivery strategies.
Hong X, Tian G, Zhu Y, Ren T. Hong X, et al. Regen Biomater. 2023 Nov 21;11:rbad103. doi: 10.1093/rb/rbad103. eCollection 2024. Regen Biomater. 2023. PMID: 38173776 Free PMC article. Review.

See all "Cited by" articles

References

1. Chien, Y. Novel Drug Delivery Systems (CRC Press, 1991).
1. Langer, R. Drug delivery and targeting. Nature 392, 5–10 (1998). - PubMed
1. Langer, R. New methods of drug delivery. Science 249, 1527–1533 (1990). - PubMed - DOI
1. Allen, T. M. & Cullis, P. R. Drug delivery systems: entering the mainstream. Science 303, 1818–1822 (2004). - PubMed - DOI
1. Gidal, B. E. et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 31, 91–99 (1998). - PubMed - DOI

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Chien, Y. Novel Drug Delivery Systems (CRC Press, 1991).

[2] Chien, Y. Novel Drug Delivery Systems (CRC Press, 1991).

[3] Langer, R. Drug delivery and targeting. Nature 392, 5–10 (1998). - PubMed

[4] Langer, R. Drug delivery and targeting. Nature 392, 5–10 (1998). - PubMed

[5] Langer, R. New methods of drug delivery. Science 249, 1527–1533 (1990). - PubMed - DOI

[6] Langer, R. New methods of drug delivery. Science 249, 1527–1533 (1990). - PubMed - DOI

[7] Allen, T. M. & Cullis, P. R. Drug delivery systems: entering the mainstream. Science 303, 1818–1822 (2004). - PubMed - DOI

[8] Allen, T. M. & Cullis, P. R. Drug delivery systems: entering the mainstream. Science 303, 1818–1822 (2004). - PubMed - DOI

[9] Gidal, B. E. et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 31, 91–99 (1998). - PubMed - DOI

[10] Gidal, B. E. et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 31, 91–99 (1998). - PubMed - DOI

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The evolution of commercial drug delivery technologies

Affiliations

The evolution of commercial drug delivery technologies

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials